Elizabeth Evans to Buprenorphine, Naloxone Drug Combination
This is a "connection" page, showing publications Elizabeth Evans has written about Buprenorphine, Naloxone Drug Combination.
Connection Strength
1.616
-
Evans EA, Yoo C, Huang D, Saxon AJ, Hser YI. Effects of access barriers and medication acceptability on buprenorphine-naloxone treatment utilization over 2?years: Results from a multisite randomized trial of adults with opioid use disorder. J Subst Abuse Treat. 2019 11; 106:19-28.
Score: 0.633
-
Evans EA, Zhu Y, Yoo C, Huang D, Hser YI. Criminal justice outcomes over 5 years after randomization to buprenorphine-naloxone or methadone treatment for opioid use disorder. Addiction. 2019 08; 114(8):1396-1404.
Score: 0.621
-
Zhu Y, Evans EA, Mooney LJ, Saxon AJ, Kelleghan A, Yoo C, Hser YI. Correlates of Long-Term Opioid Abstinence After Randomization to Methadone Versus Buprenorphine/Naloxone in a Multi-Site Trial. J Neuroimmune Pharmacol. 2018 12; 13(4):488-497.
Score: 0.148
-
Hser YI, Evans E, Huang D, Weiss R, Saxon A, Carroll KM, Woody G, Liu D, Wakim P, Matthews AG, Hatch-Maillette M, Jelstrom E, Wiest K, McLaughlin P, Ling W. Long-term outcomes after randomization to buprenorphine/naloxone versus methadone in a multi-site trial. Addiction. 2016 Apr; 111(4):695-705.
Score: 0.124
-
Zhu Y, Mooney LJ, Yoo C, Evans EA, Kelleghan A, Saxon AJ, Curtis ME, Hser YI. Psychiatric comorbidity and treatment outcomes in patients with opioid use disorder: Results from a multisite trial of buprenorphine-naloxone and methadone. Drug Alcohol Depend. 2021 11 01; 228:108996.
Score: 0.046
-
Hser YI, Zhu Y, Fei Z, Mooney LJ, Evans EA, Kelleghan A, Matthews A, Yoo C, Saxon AJ. Long-term follow-up assessment of opioid use outcomes among individuals with comorbid mental disorders and opioid use disorder treated with buprenorphine or methadone in a randomized clinical trial. Addiction. 2022 01; 117(1):151-161.
Score: 0.045